Bortezomib is an anticancer agent used for multiple myeloma in combination with other chemotherapeutic drugs. Pneumonitis and pulmonary toxicity associated with bortezomib application has been reported in a series of cases associated with multiple myeloma. A 59-year-old male patient received 16 weeks of CyBorD regimen followed by first phase of RVD regimen and bortezomib biweekly resulted in partial remission. During the second phase of RVD regimen developed cough and whitish sputum. On high resolution computed tomography showed opacities on the lungs and diagnosed as bortezomib induced interstetial lung disease. He responded to the cortecosteroid therapy and respiratory symptoms subsided. This is a clinically proven bortezomib induced interstetial lung disease on retreatment with bortezomib for a patient with relapsed multiple myeloma.